Slideshow

SGLT2 Inhibitors 2016: Year-End News Roundup

SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

We present a review of developments in SGLT2 inhibitors for the year 2016 – from the EMPA-REG OUTCOMES trial to successful dual therapy treatments to FDA advisories and safety guidelines.See the slide legends for links to the article summaries.

Related Videos
Diabetes Dialogue: Exploring New Horizons in Incretin Therapy for Diabetes and Weight Loss | Image Credit: HCPLive
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Related Content
FDA Logo | Credit: US Food and Drug Administration
December 23rd 2024

FDA Approves Generic Once-Daily GLP-1 RA for Type 2 Diabetes in Pediatric, Adult Patients

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
Insulin Resistance Amplifies Risk of Colorectal Cancer Development | Image Credit: ResearchGate
December 12th 2024

Insulin Resistance Amplifies Risk of Colorectal Cancer Development

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.